Goodwill of Avalo Therapeutics, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
Summary
Avalo Therapeutics, Inc. quarterly Goodwill in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Avalo Therapeutics, Inc. Goodwill for the quarter ending 30 Sep 2025 was $10,502,000, unchanged year-over-year.
Source SEC data
View on sec.gov
Goodwill, Quarterly (USD)
Goodwill, YoY Quarterly Change (%)

Avalo Therapeutics, Inc. Quarterly Goodwill (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $10,502,000 $0 0% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $10,502,000 $0 0% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $10,502,000 $0 0% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $10,502,000 $0 0% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $10,502,000 -$3,907,000 -27% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $10,502,000 -$3,907,000 -27% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $10,502,000 -$3,907,000 -27% 31 Mar 2024 10-Q/A 11 Jul 2024 2024 Q1
Q4 2023 $10,502,000 -$3,907,000 -27% 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $14,409,000 $0 0% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $14,409,000 $0 0% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $14,409,000 $0 0% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $14,409,000 $0 0% 31 Dec 2022 10-K 20 Mar 2025 2024 FY
Q3 2022 $14,409,000 $0 0% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $14,409,000 $0 0% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $14,409,000 $0 0% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $14,409,000 $0 0% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $14,409,000 -$88 -0% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $14,409,000 -$88 -0% 30 Jun 2021 10-Q 02 Aug 2021 2021 Q2
Q1 2021 $14,409,000 -$88 -0% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $14,409,000 -$88 -0% 31 Dec 2020 10-K 02 Mar 2022 2021 FY
Q3 2020 $14,409,088 -$2,002,035 -12% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $14,409,088 -$2,002,035 -12% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $14,409,088 -$2,002,035 -12% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $14,409,088 $0 0% 31 Dec 2019 10-K 08 Mar 2021 2020 FY
Q3 2019 $16,411,123 $0 0% 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $16,411,123 -$1,659,160 -9.2% 30 Jun 2019 10-Q 08 Aug 2019 2019 Q2
Q1 2019 $16,411,123 -$2,267,372 -12% 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $14,409,088 +$2,118,841 +17% 31 Dec 2018 10-K 11 Mar 2020 2019 FY
Q3 2018 $16,411,123 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q2 2018 $18,070,283 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 $18,678,495 31 Mar 2018 10-Q 11 May 2018 2018 Q1
Q4 2017 $12,290,247 +$12,290,247 31 Dec 2017 10-K 11 Mar 2020 2019 FY
Q4 2016 $0 31 Dec 2016 10-K 18 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.